GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Cash per Share

Pharmicell Co (XKRX:005690) Cash per Share : ₩186.67 (As of Dec. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Pharmicell Co's Cash per Share for the quarter that ended in Dec. 2024 was ₩186.67.


Pharmicell Co Cash per Share Historical Data

The historical data trend for Pharmicell Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Cash per Share Chart

Pharmicell Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 432.90 604.61 432.64 233.74 186.67

Pharmicell Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.74 179.82 83.87 168.36 186.67

Pharmicell Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Pharmicell Co's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Pharmicell Co's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmicell Co  (XKRX:005690) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Pharmicell Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines